"Entry into the Chinese medical devices market is an opportunity, given the market's size."
Itamar Medical Ltd. (TASE:ITMR) has obtained marketing approval from China's State Food and Drug Association (SFDA) for its EndoPat and WatchPat non-invasive monitoring devices for monitoring sleep disorders and cardiovascular activity, respectively. The company is readying for sales of the devices in China.
The company said that entry into the Chinese medical devices market is an opportunity, given the market's size.
The European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) have already approved both the EndoPat and WatchPat.
Itamar Medical's share price rose 6.6% by mid-afternoon to NIS 2.10, giving a market cap of NIS 263 million.
Published by Globes [online], Israel business news - www.globes-online.com - on March 27, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011